Long-Term Eslicarbazepine Acetate Extension Study.

Trial Profile

Long-Term Eslicarbazepine Acetate Extension Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 22 Jul 2017 Last checked against European Clinical Trials Database record.
    • 28 Apr 2017 Results of a post-hoc analysis (n=270) assessing efficacy and safety outcomes during the OLE for the 'true ESL monotherapy' subgroup, presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Results assessing Indices of Thyroid Function in patients from six phase III studies and their extensions (BIA2093-301,302,304,045,046,050; n=1812), presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top